October 3, 2013 (CHAPEL HILL, NC) Thought Leader Select has accepted a new key opinion leader (KOL) strategy engagement with a global biopharmaceutical leader in the treatment area of diabetes.
The client company, one of the world’s top five industry leaders in the development of medications for managing type I and type II diabetes, tabbed North Carolina’s Thought Leader Select to assist the them with upcoming initiatives in support of its entire portfolio of drugs, insulins, and delivery devices.
Thought Leader Select, headquartered in Chapel Hill, provides research and consulting services to companies in the life sciences industry, including pharmaceutical, biotechnology, medical device, and diagnostics companies. These custom-tailored services support the necessary and critical industry outreach to and collaboration with leading medical experts, the health care professionals that advance treatment options and promote better public health at regional, national, and global levels.
For the new diabetes engagement, Thought Leader Select’s in-house research team will complete a highly-specialized, hybrid assessment of the skills and experiences of thought leaders in diabetes across the United States. The assessment will include an analysis of thought leadership credentials of field-identified KOLs in diabetes, while Thought Leader Select will also run a deep-dive identification assessment of the field. These tandem assessments will ultimately form a super-roster of key opinion leaders to help the company drive its business to meet the needs of patients across the country.
As with all therapeutic area and disease state-driven analyses, Thought Leader Select’s research group will also account for significant work done by notable young and new physicians, also known as rising stars, in the treatment and research for diabetes.
Thought Leader Select’s post-research advisory support will include advising the company on strategic subjects such as advisory board and consultant selection, as well as KOL collaborations in publications and conference planning, patient advocacy work, and many other areas.
“This engagement shows some of our versatility as a group,” stated Brian Castle, Director of Global Marketing and Client Relations at Thought Leader Select. “One of our unique strengths as a company is the ability to optimize current KOL lists generated from relationships cultivated by our clients in the field with the medical experts that they serve, and then complement these KOLs with people previously less-known to the company. When we help our clients to combine these forces, getting to know as many of the medical experts as they can, great things happen in product development, patient treatment, education, and better health outcomes.”
About Thought Leader Select
Thought Leader Select is a Chapel Hill, NC-based private consulting firm serving the biopharmaceutical, medical device, and diagnostics industries with strategies, in-house research, and a suite of engagement tools and support for collaborating with and reaching out to key opinion leaders and centers of excellence in medicine.
Thought Leader Select has supported companies as they develop effective treatments to promote better patient and public health across more than 18 therapeutic areas and 50 diseases and conditions. Thought Leader Select’s customized work strengthens medical marketing initiatives, medical affairs outreach, and payer marketing strategies to support market access, pricing, and reimbursement issues.
Media Contact:
Brian Castle, Director of Global Marketing and Client Relations
Phone: 919-360-9690
E-mail: bcastle@thoughtleaderselect.com
